The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance

References

• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88–98. doi:10.1038/nrendo.2017.151
   PubMed Web of Science ®Google Scholar
• Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288–298. doi:10.1038/s41574-019-0176-8
   PubMed Web of Science ®Google Scholar
• Poon AK, Whitsel EA, Heiss G, et al. Insulin resistance and reduced cardiac autonomic function in older adults: the Atherosclerosis Risk in Communities study. BMC Cardiovasc Disord. 2020;20. doi:10.1186/s12872-020-01496-z
   PubMed Web of Science ®Google Scholar
• Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017;66:241–255. doi:10.2337/db16-0806
   PubMed Web of Science ®Google Scholar
• Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12:78–89. doi:10.1177/1479164114561992
   PubMed Web of Science ®Google Scholar
• Dong M, Wen S, Zhou L. The relationship between the blood-brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors. Diabetes Metabol Syndr Obes. 2022;15:2583–2597. doi:10.2147/DMSO.S375559
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495–502. doi:10.1038/nrendo.2011.243
   PubMed Web of Science ®Google Scholar
• Khat DZ, Husain M. Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA. Curr Diab Rep. 2018;18:45. doi:10.1007/s11892-018-1011-7
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–39. doi:10.1016/S0140-6736(18)32590-X
   PubMed Web of Science ®Google Scholar
• Brown RE, Gupta N, Aronson R. Effect of dapagliflozin on glycemic control, weight, and blood pressure in patients with type 2 diabetes attending a specialist endocrinology practice in Canada: a retrospective cohort analysis. Diabetes Technol Ther. 2017;19:685–691. doi:10.1089/dia.2017.0134
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20:520–529. doi:10.1111/dom.13103
   PubMed Web of Science ®Google Scholar
• Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity. 2014;22:1042–1049. doi:10.1002/oby.20663
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405–415. doi:10.7326/0003-4819-156-6-201203200-00003
   PubMed Web of Science ®Google Scholar
• Imbernon M, Beiroa D, Vazquez MJ, et al. Central melanin-concentrating hormone influences liver and adipose metabolism via specific hypothalamic nuclei and efferent autonomic/JNK1 pathways. Gastroenterology. 2013;144:636–649 e636. doi:10.1053/j.gastro.2012.10.051
   PubMed Web of Science ®Google Scholar
• Yahagi N. Hepatic control of energy metabolism via the autonomic nervous system. J Atheroscler Thromb. 2017;24:14–18. doi:10.5551/jat.RV16002
   PubMed Web of Science ®Google Scholar
• Lee PC, Ganguly S, Goh SY. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev. 2018;19:1630–1641. doi:10.1111/obr.12755
   PubMed Web of Science ®Google Scholar
• Cai X, Ji L, Chen Y, et al. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: a meta-analysis. J Diabetes Investig. 2017;8:510–517. doi:10.1111/jdi.12625
   PubMed Web of Science ®Google Scholar
• Lundkvist P, Pereira MJ, Katsogiannos P, et al. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: s ustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab. 2017;19:1276–1288. doi:10.1111/dom.12954
   PubMed Web of Science ®Google Scholar
• Ohta A, Kato H, Ishii S, et al. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes. Expert Opin Pharmacother. 2017;18:1433–1438. doi:10.1080/14656566.2017.1363888
   PubMed Web of Science ®Google Scholar
• Cai X, Yang W, Gao X, et al. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis. Obesity. 2018;26:70–80. doi:10.1002/oby.22066
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513–519. doi:10.1038/clpt.2008.250
   PubMed Web of Science ®Google Scholar
• Leiter LA, Yoon K-H, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, Phase 3 study. Diabetes Care. 2015;38:355–364. doi:10.2337/dc13-2762
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159–169. doi:10.1111/dom.12189
   PubMed Web of Science ®Google Scholar
• Yamamoto C, Miyoshi H, Ono K, et al. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J. 2016;63:589–596. doi:10.1507/endocrj.EJ15-0749
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190–1195. doi:10.2337/db15-1356
   PubMed Web of Science ®Google Scholar
• Xu L, Ota T. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization. Adipocyte. 2018;7:121–128. doi:10.1080/21623945.2017.1413516
   PubMed Web of Science ®Google Scholar
• Ost A, Svensson K, Ruishalme I, et al. Attenuated mTOR signaling and enhanced autophagy in adipocytes from obese patients with type 2 diabetes. Mol Med. 2010;16:235–246. doi:10.2119/molmed.2010.00023
   PubMed Web of Science ®Google Scholar
• Lambert EA, Rice T, Eikelis N, et al. Sympathetic activity and markers of cardiovascular risk in nondiabetic severely obese patients: the effect of the initial 10% weight loss. Am J Hypertens. 2014;27:1308–1315. doi:10.1093/ajh/hpu050
   PubMed Web of Science ®Google Scholar
• Costa J, Moreira A, Moreira P, Delgado L, Silva D. Effects of weight changes in the autonomic nervous system: a systematic review and meta-analysis. Clin Nutr. 2019;38:110–126. doi:10.1016/j.clnu.2018.01.006
   PubMed Web of Science ®Google Scholar
• Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2011;8:92–103. doi:10.1038/nrendo.2011.138
   PubMed Web of Science ®Google Scholar
• Buren J, Lindmark S, Renstrom F, Eriksson JW. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo? Metabolism. 2003;52:239–245. doi:10.1053/meta.2003.50041
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hai J, Cao M, et al. Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway. Int Immunopharmacol. 2013;17:714–720. doi:10.1016/j.intimp.2013.08.019
   PubMed Web of Science ®Google Scholar
• Palomer X, Pizarro-Delgado J, Barroso E, Vazquez-Carrera M. Palmitic and oleic acid: the yin and yang of fatty acids in type 2 diabetes mellitus. Trends Endocrinol Metab. 2018;29:178–190. doi:10.1016/j.tem.2017.11.009
   PubMed Web of Science ®Google Scholar
• Ader M, Stefanovski D, Kim SP, et al. Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dog. Obesity. 2014;22:1238–1245. doi:10.1002/oby.20625
   PubMed Web of Science ®Google Scholar
• Bakker LE, van Schinkel LD, Guigas B, et al. A 5-day high-fat, high-calorie diet impairs insulin sensitivity in healthy, young South Asian men but not in Caucasian men. Diabetes. 2014;63:248–258. doi:10.2337/db13-0696
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Dey D, Roy SS. Molecular mechanism of insulin resistance. J Biosci. 2007;32:405–413. doi:10.1007/s12038-007-0038-8
   PubMed Web of Science ®Google Scholar
• Coen PM, Goodpaster BH. Role of intramyocellular lipids in human health. Trends Endocrinol Metab. 2012;23:391–398. doi:10.1016/j.tem.2012.05.009
   PubMed Web of Science ®Google Scholar
• Lair B, Laurens C, Van Den Bosch B, Moro C. Novel insights and mechanisms of lipotoxicity-driven insulin resistance. Int J Mol Sci. 2020;22(1):21. doi:10.3390/ijms22010021
   PubMedGoogle Scholar
• Vorotnikov AV, Stafeev IS, Menshikov MY, Shestakova MV, Parfyonova YV. Latent inflammation and defect in adipocyte renewal as a mechanism of obesity-associated insulin resistance. Biochemistry. 2019;84:1329–1345. doi:10.1134/S0006297919110099
   PubMed Web of Science ®Google Scholar
• Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015;6:456–480. doi:10.4239/wjd.v6.i3.456
   PubMed Web of Science ®Google Scholar
• Harford KA, Reynolds CM, McGillicuddy FC, Roche HM. Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc. 2011;70:408–417. doi:10.1017/S0029665111000565
   PubMed Web of Science ®Google Scholar
• So A, Sakaguchi K, Okada Y, et al. Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor. Endocr J. 2020;67:501–507. doi:10.1507/endocrj.EJ19-0445
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515–531. doi:10.1210/er.2010-0029
   PubMed Web of Science ®Google Scholar
• Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010;1:57–92. doi:10.1007/s13300-010-0006-4
   PubMedGoogle Scholar
• Joannides CN, Mangiafico SP, Waters MF, Lamont BJ, Andrikopoulos S. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity. Diabetes Obes Metab. 2017;19:1135–1146. doi:10.1111/dom.12923
   PubMed Web of Science ®Google Scholar
• Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–514. doi:10.1172/JCI70704
   PubMed Web of Science ®Google Scholar
• Matsuba R, Matsuba I, Shimokawa M, Nagai Y, Tanaka Y. Tofogliflozin decreases body fat mass and improves peripheral insulin resistance. Diabetes Obes Metab. 2018;20:1311–1315. doi:10.1111/dom.13211
   PubMed Web of Science ®Google Scholar
• Yaribeygi H, Atkin SL, Butler AE, Sahebkar A. Sodium-glucose cotransporter inhibitors and oxidative stress: an update. J Cell Physiol. 2019;234:3231–3237. doi:10.1002/jcp.26760
   PubMed Web of Science ®Google Scholar
• Osorio H, Coronel I, Arellano A, et al. Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev. 2012;(2012):542042. doi:10.1155/2012/542042
   PubMed Web of Science ®Google Scholar
• Saha AK, Xu XJ, Balon TW, et al. Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation? Cell Cycle. 2011;10(20):3447–3451. doi:10.4161/cc.10.20.17886
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ni L, Zhang L, et al. Empagliflozin regulates the AdipoR1/p-AMPK/p-ACC pathway to alleviate lipid deposition in diabetic nephropathy. Diabetes Metab Syndr Obes. 2021;14:227–240. doi:10.2147/DMSO.S289712
   PubMed Web of Science ®Google Scholar
• Obata A, Kubota N, Kubota T, et al. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology. 2016;157:1029–1042. doi:10.1210/en.2015-1588
   PubMed Web of Science ®Google Scholar
• O’Brien TP, Jenkins EC, Estes SK, et al. Correcting postprandial hyperglycemia in Zucker diabetic fatty rats with an SGLT2 inhibitor restores glucose effectiveness in the liver and reduces insulin resistance in skeletal muscle. Diabetes. 2017;66:1172–1184. doi:10.2337/db16-1410
   PubMed Web of Science ®Google Scholar
• Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–149. doi:10.1016/j.ebiom.2017.05.028
   PubMed Web of Science ®Google Scholar
• Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol. 2012;8:709–716. doi:10.1038/nrendo.2012.114
   PubMed Web of Science ®Google Scholar
• O’Dea K, Esler M, Leonard P, Stockigt J, Nestel P. Noradrenaline turnover during under-and over-eating in normal weight subjects. Metabolism. 1982;31:896–899. doi:10.1016/0026-0495(82)90178-0
   PubMed Web of Science ®Google Scholar
• Feldstein C, Julius S. The complex interaction between overweight, hypertension, and sympathetic overactivity. J Am Soc Hypertens. 2009;3:353–365. doi:10.1016/j.jash.2009.10.001
   PubMed Web of Science ®Google Scholar
• Heisler LK, Jobst EE, Sutton GM, et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron. 2006;51:239–249. doi:10.1016/j.neuron.2006.06.004
   PubMed Web of Science ®Google Scholar
• Lindmark S, Lönn L, Wiklund U, et al. Dysregulation of the autonomic nervous system can be a link between visceral adiposity and insulin resistance. Obes Res. 2005;13:717–728. doi:10.1038/oby.2005.81
   PubMedGoogle Scholar
• Matthews VB, Elliot RH, Rudnicka C, et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens. 2017;35:2059–2068.
   PubMed Web of Science ®Google Scholar
• Herat LY, Magno AL, Rudnicka C, et al. SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection. JACC Basic Transl Sci. 2020;5:169–179. doi:10.1016/j.jacbts.2019.11.007
   PubMedGoogle Scholar
• Yu AS, Hirayama BA, Timbol G, et al. Functional expression of SGLTs in rat brain. Am J Physiol Cell Physiol. 2010;299:C1277–C1284. doi:10.1152/ajpcell.00296.2010
   PubMed Web of Science ®Google Scholar
• Nguyen T, Wen S, Gong M, et al. Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice. Diabetes Metab Syndr Obes. 2020;13:2781–2799. doi:10.2147/DMSO.S258593
   PubMed Web of Science ®Google Scholar
• Grassi G, Dell’Oro R, Facchini A, et al. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens. 2004;22(12):2363–2369. doi:10.1097/00004872-200412000-00019
   PubMed Web of Science ®Google Scholar
• Straznicky NE, Lambert GW, Masuo K, et al. Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. Am J Clin Nutr. 2009;89:27–36. doi:10.3945/ajcn.2008.26299
   PubMed Web of Science ®Google Scholar
• Aviello G, Cristiano C, Luckman SM, D’Agostino G. Brain control of appetite during sickness. Br J Pharmacol. 2021;178:2096–2110. doi:10.1111/bph.15189
   PubMed Web of Science ®Google Scholar
• Takayama S, Sakura H, Katsumori K, Wasada T, Iwamoto Y. A possible involvement of parasympathetic neuropathy on insulin resistance in patients with type 2 diabetes. Diabetes Care. 2001;24:968–969. doi:10.2337/diacare.24.5.968
   PubMed Web of Science ®Google Scholar
• Kalsbeek A, Bruinstroop E, Yi CX, et al. Hypothalamic control of energy metabolism via the autonomic nervous system. Ann N Y Acad Sci. 2010;1212(1):114–129. doi:10.1111/j.1749-6632.2010.05800.x
   PubMedGoogle Scholar
• German J, Kim F, Schwartz GJ, et al. Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve. Endocrinology. 2009;150:4502–4511. doi:10.1210/en.2009-0445
   PubMed Web of Science ®Google Scholar
• Uno K, Katagiri H, Yamada T, et al. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science. 2006;312:1656–1659. doi:10.1126/science.1126010
   PubMed Web of Science ®Google Scholar
• Izumida Y, Yahagi N, Takeuchi Y, et al. Glycogen shortage during fasting triggers liver-brain-adipose neurocircuitry to facilitate fat utilization. Nat Commun. 2013;4:2316. doi:10.1038/ncomms3316
   PubMed Web of Science ®Google Scholar
• Cassaglia PA, Hermes SM, Aicher SA, Brooks VL. Insulin acts in the arcuate nucleus to increase lumbar sympathetic nerve activity and baroreflex function in rats. J Physiol. 2011;589:1643–1662. doi:10.1113/jphysiol.2011.205575
   PubMed Web of Science ®Google Scholar
• Bruce KD, Zsombok A, Eckel RH. Lipid processing in the brain: a key regulator of systemic metabolism. Front Endocrinol. 2017;8:60. doi:10.3389/fendo.2017.00060
   PubMed Web of Science ®Google Scholar
• van den Hoek AM, van Heijningen C, Schroder-van der Elst JP, et al. Intracerebroventricular administration of neuropeptide Y induces hepatic insulin resistance via sympathetic innervation. Diabetes. 2008;57:2304–2310. doi:10.2337/db07-1658
   PubMed Web of Science ®Google Scholar
• Singhal NS, Lazar MA, Ahima RS. Central resistin induces hepatic insulin resistance via neuropeptide Y. J Neurosci. 2007;27:12924–12932. doi:10.1523/JNEUROSCI.2443-07.2007
   PubMed Web of Science ®Google Scholar
• Takeda K, Ono H, Ishikawa K, et al. Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats. BMJ Open Diabetes Res Care. 2021;9(1):e002104. doi:10.1136/bmjdrc-2020-002104
   PubMed Web of Science ®Google Scholar
• Kenney M, Weiss M, Haywood J. The paraventricular nucleus: an important component of the central neurocircuitry regulating sympathetic nerve outflow. Acta Physiol Scand. 2003;177:7–15. doi:10.1046/j.1365-201X.2003.01042.x
   PubMedGoogle Scholar
• Herat LY, Matthews J, Azzam O, Schlaich MP, Matthews VB. Targeting features of the metabolic syndrome through sympatholytic effects of SGLT2 inhibition. Curr Hypertens Rep. 2022;24:67–74. doi:10.1007/s11906-022-01170-z
   PubMed Web of Science ®Google Scholar
• Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007;6:398–405. doi:10.1016/j.cmet.2007.10.008
   PubMed Web of Science ®Google Scholar
• Yaginuma H, Banno R, Sun R, et al. Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice. J Pharmacol Sci. 2021;147:340–347. doi:10.1016/j.jphs.2021.08.010
   PubMed Web of Science ®Google Scholar
• Bartness TJ, Shrestha YB, Vaughan CH, Schwartz GJ, Song CK. Sensory and sympathetic nervous system control of white adipose tissue lipolysis. Mol Cell Endocrinol. 2010;318:34–43. doi:10.1016/j.mce.2009.08.031
   PubMed Web of Science ®Google Scholar
• Cypess AM, Weiner LS, Roberts-Toler C, et al. Activation of human brown adipose tissue by a beta 3-adrenergic receptor agonist. Cell Metab. 2015;21:33–38. doi:10.1016/j.cmet.2014.12.009
   PubMed Web of Science ®Google Scholar
• Chiba Y, Yamada T, Tsukita S, et al. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice. PLoS One. 2016;11:e0150756. doi:10.1371/journal.pone.0150756
   PubMed Web of Science ®Google Scholar
• Yang X, Liu Q, Li Y, et al. Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation. Br J Pharmacol. 2021;178:1756–1771. doi:10.1111/bph.15381
   PubMed Web of Science ®Google Scholar
• Matthews JR, Herat LY, Magno AL, et al. SGLT2 inhibitor-induced sympathoexcitation in white adipose tissue: a novel mechanism for beiging. Biomedicines. 2020;8(11):514. doi:10.3390/biomedicines8110514
   PubMed Web of Science ®Google Scholar
• Sawada Y, Izumida Y, Takeuchi Y, et al. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry. Biochem Biophys Res Commun. 2017;493:40–45. doi:10.1016/j.bbrc.2017.09.081
   PubMed Web of Science ®Google Scholar
• Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension. 1993;21:618–623. doi:10.1161/01.HYP.21.5.618
   PubMed Web of Science ®Google Scholar
• Chadderdon SM, Belcik JT, Bader L, et al. Temporal changes in skeletal muscle capillary responses and endothelial-derived vasodilators in obesity-related insulin resistance. Diabetes. 2016;65:2249–2257. doi:10.2337/db15-1574
   PubMed Web of Science ®Google Scholar
• Wu H, Ballantyne CM. Skeletal muscle inflammation and insulin resistance in obesity. J Clin Invest. 2017;127:43–54.
   PubMed Web of Science ®Google Scholar
• Hitomi H, Kiyomoto H, Nishiyama A, et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension. 2007;50:750–755. doi:10.1161/HYPERTENSIONAHA.107.093955
   PubMed Web of Science ®Google Scholar
• Mazak I, Fiebeler A, Muller DN, et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109:2792–2800. doi:10.1161/01.CIR.0000131860.80444.AB
   PubMed Web of Science ®Google Scholar
• Shin SJ, Chung S, Kim SJ, et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One. 2016;11:e0165703. doi:10.1371/journal.pone.0165703
   PubMed Web of Science ®Google Scholar
• Esler M, Rumantir M, Wiesner G, et al. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens. 2001;14:304S–309S. doi:10.1016/S0895-7061(01)02236-1
   PubMed Web of Science ®Google Scholar
• Russo B, Menduni M, Borboni P, Picconi F, Frontoni S. Autonomic nervous system in obesity and insulin-resistance-the complex interplay between leptin and central nervous system. Int J Mol Sci. 2021;23:22. doi:10.3390/ijms23010022
   PubMedGoogle Scholar
• Packer M. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes Obes Metab. 2018;20:1361–1366. doi:10.1111/dom.13229
   PubMed Web of Science ®Google Scholar